Tyrosine kinase inhibitorFDA-approvedSecond-line

Pazopanib

How it works

Blocks multiple proteins involved in cancer growth, including VEGFR, PDGFR, and c-Kit.

Cancer types

Melanoma— All patients

Efficacy

In clinical trials, around 30% of patients achieved an objective response, with median progression-free survival of approximately 4.6 months.

Side effects

Moderate

Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.

This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.